AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 92 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 0.28 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $1,748,000 | -10.9% | 78,191 | -4.6% | 0.00% | -50.0% |
Q4 2018 | $1,961,000 | -57.4% | 81,968 | -51.4% | 0.00% | 0.0% |
Q3 2018 | $4,598,000 | +87.3% | 168,514 | +84.6% | 0.00% | 0.0% |
Q2 2018 | $2,455,000 | -10.0% | 91,290 | +6.5% | 0.00% | 0.0% |
Q1 2018 | $2,729,000 | -15.6% | 85,730 | +0.3% | 0.00% | 0.0% |
Q4 2017 | $3,232,000 | +38.7% | 85,464 | -9.1% | 0.00% | 0.0% |
Q3 2017 | $2,330,000 | +19.0% | 93,985 | -1.3% | 0.00% | +100.0% |
Q2 2017 | $1,958,000 | +26.9% | 95,247 | +34.1% | 0.00% | 0.0% |
Q1 2017 | $1,543,000 | -4.8% | 71,021 | -10.3% | 0.00% | 0.0% |
Q4 2016 | $1,620,000 | +29.0% | 79,218 | -5.4% | 0.00% | 0.0% |
Q3 2016 | $1,256,000 | +38.0% | 83,728 | -0.4% | 0.00% | 0.0% |
Q2 2016 | $910,000 | +100.0% | 84,098 | +150.4% | 0.00% | – |
Q1 2016 | $455,000 | -51.4% | 33,579 | -33.9% | 0.00% | -100.0% |
Q4 2015 | $937,000 | +10.2% | 50,789 | +51.3% | 0.00% | 0.0% |
Q3 2015 | $850,000 | – | 33,579 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital LLC | 1,240,000 | $25,966,000 | 57.34% |
Foresite Capital Management II, LLC | 2,605,499 | $54,559,000 | 11.53% |
Foresite Capital Management III, LLC | 611,893 | $12,813,000 | 4.89% |
Palo Alto Investors LP | 3,471,740 | $72,698,000 | 4.84% |
SANDERS MORRIS HARRIS LLC | 486,906 | $10,196,000 | 2.47% |
Eventide Asset Management | 3,084,000 | $64,579,000 | 2.13% |
Sofinnova Investments, Inc. | 346,770 | $7,261,000 | 0.66% |
EMERALD ADVISERS, LLC | 610,511 | $12,784,000 | 0.60% |
RICE HALL JAMES & ASSOCIATES, LLC | 752,358 | $15,754,000 | 0.56% |
EMERALD MUTUAL FUND ADVISERS TRUST | 587,464 | $12,301,000 | 0.54% |